Death Receptor 5 (DR5) is a pro-apoptotic cell-surface receptor that is a potential therapeutic target in cancer. Despite the potency of DR5-targeting agents in pre-clinical models, the translation of these effects into the clinic remains disappointing. Herein, we report an alternative approach to exploiting DR5 tumor expression using antibody-targeted, chemotherapy-loaded nanoparticles. We describe the development of an optimized polymer- This novel approach may improve the clinical activity of DR5-targeted therapeutics while increasing tumor-specific delivery of systemically toxic chemotherapeutics.
Introduction
DR5 is a type I transmembrane protein belonging to the Tumor Necrosis Factor Receptor (TNFR) family. DR5, like other TNFRs, pre-assembles as receptor oligomers within the cell membrane via a pre-ligand assembly domain 1 . Binding of its cognate trimeric ligand, TNFrelated apoptosis-inducing ligand (TRAIL) induces higher order clustering of DR5 that triggers the recruitment of the adaptor molecule Fas-associated death domain and procaspase 8 to the cytoplasmic death domain of the receptor 2, 3 . The formation of this Death-Inducing
Signaling Complex (DISC) results in homo-dimerization and activation of caspase 8, which
can directly activate downstream caspases in "type I" cells or cleave the Bcl-2 family member BID, resulting in activation of BAX and induction of mitochondrial-dependent apoptosis in "type II" cells 4 .
DR5 has been proposed as a therapeutic target in various solid cancers 5 , and we have previously reported that patients with stage II and stage III colorectal tumors express significantly higher levels of DR5 compared to normal colon tissue; however, colorectal tumors also overexpress the endogenous caspase 8 inhibitor FLIP, a major mediator of resistance to DR5-induced apoptosis 6 . DR5-specific agonistic antibodies such as conatumumab have been developed to target diseases such as metastatic colorectal cancer 7, 8 , and promising effects in preclinical studies as a single agent and in combination with various chemotherapies including the topoisomerase I inhibitor irinotecan have been observed 5, 9 .
However to date, conatumumab and other DR5 agonists have failed to demonstrate convincing efficacy in clinical trials. This is thought to be a consequence of weak DR5 activation through insufficient receptor clustering in patients and/or intrinsic resistance to death receptor-initiated apoptosis 7, 8, 10 .
Previously, we have shown in vitro that the conjugation of agonistic antibodies targeting TNFR family members on the surface of polymeric nanoparticles (NP) results in enhanced avidity and potently induces receptor activation 11, 12 .
In an effort to overcome some of the current issues with targeting DR5 using antibody-based therapies, we have examined their potential in a novel antibody-conjugate platform. Here, we describe the development and evaluation of DR5-targeted and camptothecin (CPT)-loaded poly(lactic-co-glycolic) acid (PLGA) NPs optimized for in vivo application. The NPs were engineered to include both a "stealth" hydrophilic PEG corona to minimize phagocytosis in addition to DR5-specific antibodies to target tumor cells and induce apoptosis. We demonstrate the pro-apoptotic effects of the platform in vivo using HCT116 adenocarcinoma xenografts and reveal that this novel nanomedicine has the potential to overcome frequent DR5 resistance mechanisms in colorectal cancer, namely loss of BAX expression and overexpression of FLIP.
Results

Synthesis and characterization of antibody-targeted PEGylated PLGA NPs
Uniform NP populations were prepared using single emulsion evaporation with COOH-PEG3400-PLGA copolymer at 25% (w/w) blended with PLGA RG502H (Fig. 1a and Table   1 ). The exposed carboxyl groups on the surface deriving from the functionalized copolymer allowed subsequent conjugation of the DR5-specific antibody conatumumab via free amino groups within the antibody chain, using carbodiimide chemistry (16.6 ± 4.2 µg per mg NP).
Furthermore, the presence of the PEG corona significantly inhibited phagocytosis by murine macrophages (Fig. 1b) . For drug-loaded NP preparations, CPT was mixed with the polymer in the organic phase before emulsification. As observed previously, the inclusion of CPT in the formulation increased the size and heterogeneity of the NP population 12 . Similarly, increases of NP size distribution were obtained for DR5-NPs due to the conjugation of high molecular weight antibodies to the NP surface (Table 1) . Further confirmation of the size distribution (~200 nm) of blank and CPT-loaded DR5-NPs was obtained by scanning electron microscopy (SEM) (Fig. 1c) . Finally, the controlled release profile of the drug from the particles was monitored in PBS containing 50% serum at 37 °C, where a cumulative release of the compound was observed over a period of 6 days (Fig. 1d) .
DR5-NPs initiate apoptosis
The ability of the DR5-NPs to bind to colon adenocarcinoma HCT116 cells was next examined. Confocal microscopy using NPs formulated with a fluorescently labeled PLGA firstly revealed that DR5 targeting enhanced the binding of the NPs to the cells. DR5 costaining revealed broad distribution of DR5 throughout the cells and some co-localization with DR5-NPs, which was not evident with nude NPs; indicating that the antibodyconjugated NPs could bind to DR5 on the cells (Fig. 2a) . To confirm this interaction more conclusively, Western blot analysis of the protein complexes interacting with the NPs was performed. This showed that the DR5-NPs (but not the nude or IgG control NPs) were bound to DR5 in a complex with caspase 8 (Fig. 2b) . Caspase 8 was present in this complex predominantly in its cleaved p41/43-forms, but also in its p18-form indicative of its dimerization and activation at the DR5 DISC. Fully processed p18-caspase 8 can remain bound at the DISC or be released into the cytoplasm 13 , explaining its presence in both the supernatant and precipitated fraction. In agreement with the observed recruitment and processing of procaspase 8, enzymatic activity assays confirmed significantly increased levels of both caspase 8 and executioner caspases 3/7 following treatment with DR5-NPs (Fig. 2c) . Control NPs and free anti-DR5 antibody were incapable of inducing this effect. The enhanced receptor activation induced by DR5-NPs over free antibody is the consequence of the simultaneous presentation of multiple binding paratopes on the NP surface that efficiently induces DR5 clustering and DISC formation. Furthermore, in a competition assay, caspase 8 activity was significantly reduced when the cells were pre-incubated with excess free DR5-specific antibody (Fig. S1a) , further highlighting the specificity of this interaction.
The impact of NP-mediated DR5 clustering on cell viability was next assessed using MTT assays, which revealed that DR5-NPs induce a more pronounced cytotoxic effect than free antibody (Fig. 2d) . Moreover, colony formation was clearly reduced after only 1 h of incubation with DR5-NPs, whereas free antibody did not impact on clonogenic survival (Fig.   2e ). The observed pro-apoptotic effect was DR5-dependent as shown by receptor silencing using siRNA (Fig. S1b and c) . Furthermore, normal colon fibroblasts (CCD-18Co), which express low levels of DR5, are significantly less sensitive to DR5-NPs than HCT116 tumor cells (Fig. S2) . Finally, we assessed the stability of the DR5-NPs following incubation in 50% serum at 37 °C. This demonstrated that the antibody remained on the NP surface up to 96 h ( Fig. 2f) and that within this timeframe, the NPs maintained their ability to significantly activate caspase 8 (Fig. 2g) .
CPT loading enhances apoptosis induced by DR5-NPs
Next, we investigated the potential of exploiting this targeted NP formulation as a carrier for the chemotherapeutic drug CPT. Incubation with CPT-loaded NPs caused S-and G2/M-arrest within 24 h indicative of CPT-induced DNA damage (Fig. 3a) . Furthermore, it was shown that CPT loading induced Thr68-phosphorylation of Chk2 (pThr68-Chk2) (Fig. 3b) ; Chk2 is an upstream kinase activated by ATM in response to DNA double-strand breaks such as those caused by topoisomerase-I inhibition 14, 15 . Apoptotic cell death was detected by flow cytometry in 40% of the cells 24 h after treatment with DR5-NPs, and this was enhanced to 70% when CPT was loaded into the NP core (Fig. 3c) 16 were markedly sensitized to DR5-mediated cell death through the co-delivery of CPT (Fig. 3d) . Blank NPs had no effect on cell viability at the applied polymer concentrations (Fig. S3 ).
DR5-targeting potentiates the anti-tumor effects of CPT
The therapeutic effects of DR5-NPs were next evaluated in vivo using athymic mice bearing HCT116 xenografts. The tumor volume was reduced by ~35% in mice treated with DR5-NPs over both PBS and control-IgG conjugated NPs by day 22 following five serial treatments.
These effects were comparable to the freely administered anti-DR5 antibody without significant weight loss during the time of treatment (Fig. 4a and b) . The effectiveness of the antibody, free or NP-bound, was clearly evident through immunohistochemical staining of cleaved caspase 3, highlighting the ability of the antibody to initiate apoptosis in both these treatment groups (Fig. 4c) . It has recently been shown that free DR5-targeted antibodies are cross-linked through Fcγ receptors (FcγR) that are found on a range of immune cells 17-19 and therefore, it was not unexpected that free anti-DR5 antibodies exhibited activity in murine tumor models. The therapeutic effects generated by inclusion of CPT in the NP formulations were also assessed. At the study end point, tumor growth was significantly inhibited by 65%
following serial administration of CPT nude NPs, and this anti-tumor activity was further enhanced when the NPs were coated with DR5-targeting antibodies inhibiting tumor growth by 74% (Fig. 4a) . To determine whether NP-delivered CPT induced DNA damage, the tumor lysates were analyzed for pThr68-Chk2. Significant increases in pThr68-Chk2 were observed in tumors from animals treated with CPT nude NPs and CPT DR5-NPs compared to tumors from blank IgG-NP treated mice (Fig. 4d) .
Collectively, these results demonstrate that both active pharmaceutical ingredients of the nanoconjugate have produced therapeutic effects in vivo and that the combination of CPT encapsulated in DR5-NPs yields superior anti-tumor activity.
DR5-NPs overcome BAX deficiency in combination with CPT
Intrinsic resistance of tumors toward DR5-mediated apoptosis may be the major factor , and the pre-treatment with this small molecule inhibitor sensitized the resistant BAX null cells to DR5-NP-mediated apoptosis (Fig. 5b) ; similar effects were observed using an XIAP-targeted siRNA (Fig. S4 ). The effects caused by birinapant were not as dramatic as observed following pre-treatment with CPT ( Fig. S5 ), suggesting that other molecular events favoring cell death are induced by CPT, such as upregulation of DR5 cell surface expression, which was detected following CPT treatment (Fig. S6 ).
On the basis of these findings, a sequential treatment strategy was designed for treating Bax null cells with CPT DR5-NPs (and associated controls) as outlined in Fig. 5c . Induction of cell cycle arrest and onset of apoptosis in the cells was examined by flow cytometry.
Following the initial 24 h treatment with CPT loaded NPs, cell cycle arrest in S-and G2/Mphases was apparent, but none of the treatment groups induced cell death as indicated by a lack of cells in the sub-G1 phase (Fig. 5c, 24 h ). The CPT-induced G2/M-arrest was more pronounced after subsequent incubation in fresh medium for a further 24 h and a small cell population (~4%) underwent cell death (Fig. 5c, 48 h ). However, after re-treatment for only 6 h, the CPT DR5-NPs induced a significant increase in cell death, whereas the other NP treatment groups were unable to induce significant effects compared to cells treated with blank nude NPs (Fig. 5c, 54 h ). This corresponded with significantly increased activation of caspase 8 and caspases 3/7 (Fig. 5d) , and PARP cleavage (Fig. 5e) . Further protein analysis also revealed that DR5 was upregulated 24 h following treatment with CPT loaded NPs, and this effect was enhanced after 48 h, the point of re-treatment. At this time-point, and consistent with earlier results (Fig. 5a) , XIAP was downregulated in cells treated with CPT loaded NPs. Upon re-treatment of the cells with the CPT DR5-NPs, DR5 expression was decreased (Fig. 5e) ; this is most likely due to receptor internalization and lysosomal degradation as proposed by Austin et al.
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. We also analysed levels of BAK, which functions similarly to BAX by forming pores in the outer mitochondrial membrane during apoptosis 26 .
Small alterations in BAK levels were observed but these did not correlate with the enhanced induction of apoptosis with CPT DR5-NPs. Taken together, these results demonstrate that repeated treatments with CPT DR5-NPs are able to overcome apoptotic resistance in colorectal cancer cells caused by the absence of BAX through downregulation of XIAP and simultaneous upregulation of DR5.
DR5-NPs overcome apoptosis resistance mediated by FLIP
Another major resistance mechanism to DR5-initiated apoptosis is upregulation of FLIP, which is an endogenous inhibitor of caspase 8 and can cause resistance to DR5-mediated apoptosis 27 . FLIP is found overexpressed in tissues of a range of malignancies including colorectal carcinoma 6, 28, 29 . Firstly, we examined the impact of CPT treatment on endogenous FLIP proteins in wild-type HCT116 cells. Treatment with a concentration of CPT (1 µM) that induced PARP cleavage within 24 h markedly downregulated FLIP long (FLIPL) levels (Fig. 6a) . This effect was accompanied by increasing activity of caspase 8 with ascending CPT concentrations, which reached significance at the highest CPT concentration (Fig. 6b) . As no decrease in FLIP mRNA levels were observed in cells treated with 1 µM CPT for 24 h (Fig. S7) , these results suggest that FLIP is degraded following treatment with this concentration of CPT, resulting in activation of caspase 8. To investigate the effect of FLIP overexpression on DR5-NP-induced apoptosis and the potential to overcome this resistance mechanism by co-delivery of CPT, we investigated HCT116 cells that overexpress the two main FLIP splice isoforms; FLIPL and FLIP short (FLIPS). Similar to the observations with endogenous protein, both exogenous splice variants were downregulated following CPT treatment, and this correlated with PARP cleavage (Fig. 6c) .
Notably, overexpression of FLIPL did not impact on the ability of DR5-NPs to induce apoptosis following treatment with DR5-NPs (Fig. 6d) . In contrast, FLIPS overexpression reduced apoptosis, however, the impact of FLIPS overexpression was significantly less when CPT was encapsulated into DR5-NPs; this reflects the downregulation of exogenous FLIPS in response to treatment with both CPT-loaded NP formulations (Fig. 6e) . The differential effects observed in the two FLIP overexpressing cell lines are most likely due to the different expression levels of the two exogenous FLIP proteins with FLIPS overexpressed ~4 times more highly (Fig. 6c) , and reflected by the observation that FLIPS overexpression was very effective at blocking apoptosis induced by co-treatment with recombinant human TRAIL (rhTRAIL) and CPT (Fig. S8 ). These results demonstrate that DR5-NPs can activate the extrinsic apoptotic pathway despite moderate (FLIPL model) and high (FLIPS model) overexpression of FLIP, and this effect is further enhanced by co-delivery of CPT.
Discussion
In this current work, we have developed a polymeric NP drug delivery system suitable for in vivo application that incorporates an antibody therapeutic targeting DR5 and chemotherapy payload. The therapeutic effectiveness of this modality was validated in vivo, and moreover, we showed that common resistance mechanisms to DR5-initiated apoptosis could be overcome by this approach.
We have previously examined the conjugation of antibodies to the surface of PLGA-based
NPs to elicit improved uptake in tumor cell populations in vitro 11, 12 . PLGA is a biodegradable and biocompatible polymer approved in various medical applications 30 .
However, these polymeric NPs are hydrophobic and once in circulation, serum proteins can rapidly aggregate on the surface of such hydrophobic nanomaterials promoting macrophage uptake 31 . The inclusion of a surface layer of hydrophilic polymers such as PEG can counteract macrophage uptake and reduce the rapid NP clearance that occurs in the organs of the mononuclear phagocyte system 32 . This has been shown to therefore enhance the half-life of PEGylated PLGA-based NPs 33, 34 . Here, we successfully incorporated a carboxylfunctionalized PEG3400 into the formulation and, in agreement with previous studies, found that macrophage uptake of the NPs was diminished.
The conjugation of a DR5-targeting antibody to the surface of these NPs was shown to promote binding to the target receptor and induce formation of the apoptosis-inducing DR5 DISC. Although the presentation of the DR5 antibody on the surface of the NP significantly increased apoptosis compared to free antibody in vitro, this differential effect was not evident in vivo. It is well characterized that the free anti-DR5 antibody with only two paratopes is inefficient at promoting higher-order clustering and activation of DR5 in cell-based assays 9 .
However, once applied in murine in vivo studies, it does achieve agonistic activity comparable to DR5-NPs. This phenomenon is dependent on FcγR engagement of the antibody on myeloid cells which facilitates multiple paratope presentation that in turn drives receptor activation on the surface of the tumor cells [17] [18] [19] . The clinical significance of this effect in patients remains poorly characterized, and FcγR polymorphisms affecting antibody affinity may dictate the effectiveness of the drug 8, 35 . However, this issue is circumvented by our novel approach of using NPs to present multiple paratopes to drive DR5 activation on the surface of tumor cells.
Considering the physiological role of TRAIL/DR5 in tumor immune surveillance 36 , it is not surprising that many cancer cells develop resistance mechanisms in order to escape destruction mediated by TRAIL-expressing immune cells 10 . We hypothesized that efficient receptor crosslinking through DR5-NPs, in combination with the delivery of a cytotoxic agent, may enhance DR5-mediated apoptosis and more importantly help to overcome frequently occurring resistance mechanisms in cancer cells. CPT was selected as the cargo chemotherapy in this approach but issues with its solubility, stability and toxicity profile have led to the development and clinical application of derivatives, namely irinotecan and topotecan 37 . However, the promising clinical results of CRLX101, a polymeric nanoformulation of CPT currently investigated in clinical phase II trials, clearly highlight the therapeutic potential of this highly potent compound when delivered appropriately 38 . CPT NPs exhibited significant anti-tumor effects in HCT116 xenografts that were markedly enhanced when the NPs were functionalized with DR5 antibody; this is consistent with the results of combination studies of conatumumab with irinotecan in vitro and in vivo 9 . The HCT116 tumors proved highly sensitive to the levels of CPT encapsulated in the NPs, and this may have partially masked the therapeutic advantage of the conjugated DR5 antibodies.
Nonetheless, the results obtained from the DR5-targeted NP groups clearly show that the conjugates were able to localize to the tumor and initiate apoptosis. Given that this antibody does not cross-react with murine DR5, future studies will require a species-matched agonistic antibody in order to undertake detailed biodistribution and pharmacokinetic analyses; examining parameters such as particle size, antibody orientation and use of antibody fragments to optimize the pro-apoptotic effects and evaluate the ability of the antibodies to enhance targeting of the NP to tumors.
Another key consideration in resistance of tumors to extrinsic apoptosis is the requirement for mitochondrial amplification of an extrinsic apoptotic signal, which determines whether cells are classified as type I (not required) and type II cells (required) 10 . The deregulation of proteins within the mitochondrial pathway through overexpression of anti-apoptotic Bcl-2 39 and Bcl-XL 40 FLIP is a key regulator of death receptor-mediated apoptosis and is found overexpressed in a range of malignancies 6, 28, 29, 44 . High expression of FLIP is proposed to contribute to resistance to death receptor-targeted therapy by disrupting procaspase 8 homo-dimerization and activation at the DISC 10, 27 . The results presented herein indicate that the enhanced receptor oligomerization induced by DR5-NPs can overcome FLIP-mediated resistance to DR5-induced apoptosis when FLIP is overexpressed at moderate levels (FLIPL model).
Moreover, even in cells with high levels of FLIP expression (FLIPS model), DR5-NPs induced high levels of apoptosis, and these cells could be further sensitized through incorporation of CPT into the NP core, as co-delivery of CPT resulted in FLIP downregulation. Taken together, these results highlight the potential of this DR5-targeted platform to overcome these resistance mechanisms.
Given the recent advances in clinical application of polymer-based nanotherapeutics 38, 45, 46 and promising results with antibody drug conjugates (ADCs) such as Trastuzumab emtansine (T-DM1) 47 , therapies that bring together anti-cancer drugs in a single therapeutic entity represent exciting new approaches for the treatment of cancer. In this study we have demonstrated the therapeutic potential of using drug-loaded, tumor-targeted NPs as an alternative ADC strategy.
Materials and Methods
NP synthesis
NPs 
Cell culture
The HCT116 wild-type and Bax -/-mutant cell lines were kindly provided by Professor Bert Vogelstein (Johns Hopkins University) and cultured in McCoy 5A medium supplemented with 10% FBS. HCT116 cell lines overexpressing FLIPS and FLIPL were generated as described previously 48 . The Raw 264.7, RKO and HT-29 cells were obtained from ATCC, LoVo cells from ECACC and maintained in supplemented DMEM.
NP uptake analysis
Raw 264.7 cells were incubated with 0.1 mg/mL of rhodamine 6G-loaded NPs for 1 h and washed with PBS (2x), stripping buffer (50 mM glycine, 150 mM NaCl, pH3) and PBS (1x)
before PE fluorescence was analyzed by flow cytometry. For confocal microscopy, the cells were incubated with rhodamine B-labeled NPs (0.2 mg/mL) for 1 h and then washed in PBS (3x), stripping buffer (1x) and PBS (3x). The cells were fixed using 4% paraformaldehyde followed by further washing steps in PBS (3x). DR5 was stained using anti-DR5 antibody 
